Literature DB >> 32065247

[Anal dysplasia and anal cancer].

Ulrike Wieland1, Frank Oellig2, Alexander Kreuter3.   

Abstract

Anal intraepithelial neoplasia (AIN) and 89-100% of anal cancers are caused by persistent infections with high-risk (HR) human papillomaviruses (HPV). In HIV-positive patients, anal HPV infection and AIN are very common and these patients have a greatly increased risk of developing anal cancer. However, a continuous increase in the incidence of anal cancer has also been observed in the general population in recent decades. AIN can clinically present in diverse manners. In HIV-positive patients AIN can be hidden in condylomas. Furthermore, 3-14% of high-grade AIN progress to anal cancer within 5 years. Therefore, screening examinations should be offered to patients with an increased risk for anal cancer. The treatment options for AIN are similar to those for condylomas. HIV-positive patients with controlled immune status and HIV-negative patients with anal cancer respond comparably well to combined radiochemotherapy. A German-language AWMF S3 guideline for anal cancer will be available in 2020. In HIV-positive patients over 26 years of age, HPV vaccination showed no effect in a controlled phase‑3 study. To prevent AIN and anal cancer in the future, HPV vaccination rates need to be increased in HPV-naïve girls and boys.

Entities:  

Keywords:  Anal intraepithelial neoplasia; Cancer screening; HIV seropositivity; HPV vaccines; Human papillomavirus

Mesh:

Substances:

Year:  2020        PMID: 32065247     DOI: 10.1007/s00105-020-04548-9

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  60 in total

1.  Pre-treatment magnetic resonance-based texture features as potential imaging biomarkers for predicting event free survival in anal cancer treated by chemoradiotherapy.

Authors:  Arnaud Hocquelet; Thibaut Auriac; Cynthia Perier; Clarisse Dromain; Marie Meyer; Jean-Baptiste Pinaquy; Alban Denys; Hervé Trillaud; Baudouin Denis De Senneville; Véronique Vendrely
Journal:  Eur Radiol       Date:  2018-02-05       Impact factor: 5.315

2.  Prevalence and risk factors for human papillomavirus infection of the anal canal in human immunodeficiency virus (HIV)-positive and HIV-negative homosexual men.

Authors:  J M Palefsky; E A Holly; M L Ralston; N Jay
Journal:  J Infect Dis       Date:  1998-02       Impact factor: 5.226

3.  Impact of the quadrivalent HPV vaccine on disease recurrence in men exposed to HPV Infection: a randomized study.

Authors:  Enis Rauf Coskuner; Tayyar Alp Ozkan; Ayhan Karakose; Ozdal Dillioglugil; Ibrahim Cevik
Journal:  J Sex Med       Date:  2014-08-14       Impact factor: 3.802

4.  Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205).

Authors:  Madhur K Garg; Fengmin Zhao; Joseph A Sparano; Joel Palefsky; Richard Whittington; Edith P Mitchell; Mary F Mulcahy; Karin I Armstrong; Nassim H Nabbout; Shalom Kalnicki; Bassel F El-Rayes; Adedayo A Onitilo; Daniel J Moriarty; Thomas J Fitzgerald; Al B Benson
Journal:  J Clin Oncol       Date:  2017-01-09       Impact factor: 44.544

5.  Prevalence of and Risk Factors for Anal High-grade Squamous Intraepithelial Lesions in Women Living with Human Immunodeficiency Virus.

Authors:  Elizabeth A Stier; Shelly Y Lensing; Teresa M Darragh; Ashish A Deshmukh; Mark H Einstein; Joel M Palefsky; Naomi Jay; J Michael Berry-Lawhorn; Timothy Wilkin; Dorothy J Wiley; Luis F Barroso; Ross D Cranston; Rebecca Levine; Humberto M Guiot; Audrey L French; Deborah Citron; M Katayoon Rezaei; Stephen E Goldstone; Elizabeth Chiao
Journal:  Clin Infect Dis       Date:  2020-04-10       Impact factor: 9.079

6.  Cumulative Incidence of Cancer Among Persons With HIV in North America: A Cohort Study.

Authors:  Michael J Silverberg; Bryan Lau; Chad J Achenbach; Yuezhou Jing; Keri N Althoff; Gypsyamber D'Souza; Eric A Engels; Nancy A Hessol; John T Brooks; Ann N Burchell; M John Gill; James J Goedert; Robert Hogg; Michael A Horberg; Gregory D Kirk; Mari M Kitahata; Philip T Korthuis; William C Mathews; Angel Mayor; Sharada P Modur; Sonia Napravnik; Richard M Novak; Pragna Patel; Anita R Rachlis; Timothy R Sterling; James H Willig; Amy C Justice; Richard D Moore; Robert Dubrow
Journal:  Ann Intern Med       Date:  2015-10-06       Impact factor: 25.391

7.  Human papillomavirus infection and cytologic abnormalities of the anus and cervix among HIV-infected women in the study to understand the natural history of HIV/AIDS in the era of effective therapy (the SUN study).

Authors:  Erna Milunka Kojic; Susan Cu-Uvin; Lois Conley; Tim Bush; Juanita Onyekwuluje; David C Swan; Elizabeth R Unger; Keith Henry; John H Hammer; Edgar T Overton; Teresa M Darragh; Joel M Palefsky; Claudia Vellozzi; Pragna Patel; John T Brooks
Journal:  Sex Transm Dis       Date:  2011-04       Impact factor: 2.830

8.  Recent Trends in Squamous Cell Carcinoma of the Anus Incidence and Mortality in the United States, 2001-2015.

Authors:  Ashish A Deshmukh; Ryan Suk; Meredith S Shiels; Kalyani Sonawane; Alan G Nyitray; Yuxin Liu; Michael M Gaisa; Joel M Palefsky; Keith Sigel
Journal:  J Natl Cancer Inst       Date:  2020-08-01       Impact factor: 13.506

9.  Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment.

Authors:  Allan Hildesheim; Paula Gonzalez; Aimee R Kreimer; Sholom Wacholder; John Schussler; Ana C Rodriguez; Carolina Porras; Mark Schiffman; Mary Sidawy; John T Schiller; Douglas R Lowy; Rolando Herrero
Journal:  Am J Obstet Gynecol       Date:  2016-02-16       Impact factor: 8.661

10.  Anal Squamous Intraepithelial Lesions (SILs) in Human Immunodeficiency Virus-Positive Men Who Have Sex With Men: Incidence and Risk Factors of SIL and of Progression and Clearance of Low-Grade SILs.

Authors:  V W Jongen; O Richel; E Marra; M L Siegenbeek van Heukelom; A van Eeden; H J C de Vries; I Cairo; J M Prins; M F Schim van der Loeff
Journal:  J Infect Dis       Date:  2020-06-16       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.